Kerwin Medical Center

What Kerwin Medical Center does

Kerwin Medical Center (KMC) is a privately held, founder-led clinical research site established in 2018 by Dr. Diana R. Kerwin, MD, CPI, and headquartered on the Presbyterian Hospital Dallas campus with a second location in Oak Cliff opened in late 2024. The company specializes in conducting Phase 1, 2, and 3 clinical trials for Alzheimer's disease and related dementias (ADRD), including mild cognitive impairment, frontotemporal dementia, Lewy-body dementia, vascular dementia, Parkinson's disease, progressive supranuclear palsy, and prevention of cognitive decline. Its core technical capabilities center on cognitive assessments and memory screenings, MRI and PET imaging coordination, lumbar punctures, and on-site sterile compounding research pharmacy operations under USP <797> compliance.

KMC operates as a professional services site, generating revenue through per-patient grants and procedure fees paid by pharmaceutical and biotech sponsors — including AbbVie, Biogen, Roche, Novartis, Eli Lilly, Bristol-Myers Squibb, Denali Therapeutics, Biohaven Pharmaceuticals, and Prothena — to enroll and treat qualified study participants according to sponsor protocols. Patient participation is provided at no cost with no insurance required. The company serves three constituencies: patients and families seeking access to investigational ADRD therapies; caregivers requiring support and education; and enterprise pharmaceutical sponsors needing qualified research sites with deep patient access in the DFW Metroplex. Its go-to-market blends enterprise sponsor engagement, direct-to-consumer patient intake via online prescreening forms, and a community-led outreach program anchored by a dedicated coordinator and the founder's media presence.

The organization maintains an academic partnership with UT Southwestern Medical Center (Dr. Kerwin serves as Adjunct Assistant Professor), is bilingual in English and Spanish, and holds community partnerships with the Alzheimer's Association, CurePSP, DIAN, Belmont Village, and Bristol Hospice. Awards include D CEO's 2025 Excellence in Healthcare Medical Research finalist recognition and the Oak Cliff Chamber of Commerce New Business of the Year award. Revenue is not publicly disclosed; the company is wholly owned by its founder with no institutional investors identified.

Name

Kerwin Medical Center

Legal name

Kerwin Medical Center

Website

https://kerwinmedical.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Kerwin Medical Center is a privately held Dallas-based clinical research site founded in 2018 by Dr. Diana Kerwin, conducting Phase 1-3 trials for Alzheimer's and related dementias on behalf of major pharmaceutical sponsors at two Dallas-area locations.

Ownership category

akta.pro rank

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales, Technology or R&D

Revenue model

1. Clinical Trial Sponsorship Revenue: Kerwin Medical Center generates revenue by serving as a clinical trial site for pharmaceutical and biotech companies. Sponsors (such as AbbVie, Biogen, Roche, Novartis, Lilly, Bristol-Myers Squibb, Denali, Biohaven, and others) contract with KMC to conduct Phase 1, 2, and 3 clinical trials for Alzheimer's disease and related dementias. Revenue is earned by enrolling and treating qualified study participants according to sponsored research protocols.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Kerwin Medical Center operates a dedicated clinical research site that enrolls and treats patients in Phase 1, 2, and 3 clinical trials for Alzheimer's disease, mild cognitive impairment, frontotemporal dementia, Lewy-body dementia, vascular dementia, Parkinson's disease, progressive supranuclear palsy, and cognitive decline prevention. The center contracts with pharmaceutical sponsors and conducts cognitive assessments, imaging coordination, infusions, and clinical procedures at two Dallas-area locations, supplemented by memory screening services for prospective participants.

Product overview

Kerwin Medical Center is a clinical research center offering a unified suite of services focused on neurodegenerative disease research, primarily Alzheimer's disease and related dementias. The core offering is clinical research trials conducted in partnership with pharmaceutical sponsors, supported by patient pre-screening services (KMC Pre-Screen Packet, Medical Records Release Form), cognitive memory screening assessments at two Dallas locations, and community support resource referrals. The center does not operate a software product platform but provides research services directly to patients and families seeking to participate in clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Research Trials Phase 1, 2, and 3 clinical trials for Alzheimer's disease, mild cognitive impairment, frontotemporal dementia, Lewy-body dementia, vascular dementia, Parkinson's disease, progressive supranuclear palsy, and cognitive decline prevention. Conducted under sponsored research protocols with major pharmaceutical and biotech sponsors; matches qualified patients to participating studies at KMC's two Dallas locations.

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

15 partnerships are on record, tiered core and minor.

• AbbViecoreStrategic or Co-development PartnerAbbVie has partnered with KMC as a sponsor for clinical trials in Alzheimer's disease and related dementias. KMC has served as a study partner site for AbbVie trials, including an Alzheimer's trial involving study participants and their care partners.
• BiogencoreStrategic or Co-development PartnerBiogen has worked with KMC as a clinical trial sponsor, conducting research in Alzheimer's disease. KMC is listed as a site for Biogen clinical studies.
• RochecoreStrategic or Co-development PartnerRoche has partnered with KMC for dementia-related clinical trials. Dr. Kerwin appeared in a Roche AD Taxi segment discussing biomarkers for dementia diagnosis.
• NovartiscoreStrategic or Co-development PartnerNovartis has sponsored clinical trials at KMC, including Alzheimer's prevention trials. KMC has conducted Novartis-sponsored research studies.
• Eli Lilly and CompanycoreStrategic or Co-development PartnerLilly has worked with KMC as a clinical trial sponsor for Alzheimer's disease research.
• Bristol-Myers SquibbminorStrategic or Co-development PartnerBristol-Myers Squibb has partnered with KMC as a clinical trial sponsor for dementia-related research.
• Denali TherapeuticsminorStrategic or Co-development PartnerDenali has worked with KMC as a clinical trial sponsor for neurodegenerative disease research.
• Biohaven PharmaceuticalsminorStrategic or Co-development PartnerBiohaven has partnered with KMC for clinical trials in related therapeutic areas.
• ProthenaminorStrategic or Co-development PartnerProthena has worked with KMC as a clinical trial sponsor for clinical studies.
• Alzheimer's AssociationcoreStrategic or Co-development PartnerThe Alzheimer's Association is a community support partner. Dr. Kerwin previously served on the National Board of Directors for the Alzheimer's Association and as local Dallas Chapter Board Chair. The center references the association's resources for patient education.
• CurePSPminorStrategic or Co-development PartnerCurePSP is listed as a community support organization on KMC's community resources page. The center has participated in CurePSP-related clinical trials and board activities.
• Dominantly Inherited Alzheimer Network (DIAN)minorStrategic or Co-development PartnerDIAN and DIAN Trials Unit (DIAN TU) at Washington University have worked with KMC on clinical trials for inherited forms of Alzheimer's disease.
• University of Texas Southwestern Medical Center (UTSW)coreStrategic or Co-development PartnerKMC maintains an academic partnership with UTSW. Dr. Kerwin serves as Adjunct Assistant Professor in the Department of Neurology and Neuro-Therapeutics. Team members including Dr. Khera and Dr. Harris have affiliations with UTSW. KMC serves as clinical faculty for training medical students.
• Belmont VillageminorStrategic or Co-development PartnerBelmont Village Turtle Creek Dallas is listed as a residential resource partner for patients and families seeking senior living options.
• Bristol Hospice DallasminorStrategic or Co-development PartnerBristol Hospice Dallas is listed as a residential care resource for patients and families.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Customer concentration

• Facebookfacebook.com/DrKerwin
• LinkedInlinkedin.com/company/kerwin-research-center

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kerwin Medical Center